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Abstract
Aurora A is an oncogenic serine/threonine kinase which can cause cell transformation and centrosome amplification when
over-expressed. Human breast tumors show excess Aurora A and phospho-centrin in amplified centrosomes. Here, we show
that Aurora A mediates the phosphorylation of and localizes with centrin at the centrosome, with both proteins reaching
maximum abundance from prophase through metaphase, followed by their precipitous loss in late stages of mitosis. Over-
expression of Aurora A results in excess phospho-centrin and centrosome amplification. In contrast, centrosome
amplification is not seen in cells over-expressing Aurora A in the presence of a recombinant centrin mutant lacking the
serine phosphorylation site at residue 170. Expression of a kinase dead Aurora A results in a decrease in mitotic index and
abrogation of centrin phosphorylation. Finally, a recombinant centrin mutation that mimics centrin phosphorylation
increases centrin’s stability against APC/C-mediated proteasomal degradation. Taken together, these results suggest that
the stability of centrin is regulated in part by Aurora A, and that excess phosphorylated centrin may promote centrosome
amplification in cancer.
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Introduction
The centrosome aids in the assembly of the bipolar mitotic
spindle and in maintenance of cell polarity. Centrosome
abnormalities are observed in many cancers and have been shown
to drive chromosomal instability (CIN) and aneuploidy. Several
key mitotic kinases, including the Plk, NEK, and Aurora families
[1,2,3,4,5,6], and elevated levels of phosphorylated centrosomal
proteins, including centrin [7], have been implicated in centro-
some amplification in cancer.
Aurora A is frequently over-expressed in breast and bladder
cancer and its ectopic expression causes centrosome amplification
and CIN in cell lines and in vivo models [8,9]. Studies using rat and
mouse mammary cancer models demonstrate that Aurora A over-
expression and genomic instability are early events in tumor
progression [10,11,12]. Both Aurora A and the tumor suppressor
p53 [13,14] have been implicated in control of genomic stability
and centrosome amplification. Interestingly, phosphorylation of
p53 by Aurora A leads to its inactivation and degradation [15,16].
Centrin, a small EF-hand phospho-protein, is located in the
centrosome, pericentriolar material, throughout the cytoplasm,
and at times, in the nucleus [17,18,19]. Despite its ubiquity,
centrin is a reliable marker for centrioles because of its highly focal
centriolar concentration [20]. Centrin is essential to centriole
duplication, as demonstrated by centriole loss and ultimately cell
death when centrin is knocked down [21]. Centrin is phosphor-
ylated at G2/M [17], yet little is known about the regulation of
centrin stability and abundance during the cell cycle. Because both
Aurora A and centrin have been implicated in regulating
centrosome structure and function, we hypothesized that post-
translational centrin modifications driven by Aurora A regulate its
stability and abundance. Given that centrin is required for
centriole duplication, we also investigated whether alterations in
centrin stability lead to centrosome amplification.
Results
We performed immunofluorescence confocal microscopy on
HeLa cells stained with antibodies directed against Aurora A and
total and phosphorylated-S170 centrin (p-S170 centrin) to
determine the localization of p-S170 centrin and Aurora A in
intact cells. As demonstrated in Figure 1A, both Aurora A and p-
S170 centrin localize at the centrosome from prophase through
metaphase. Phospho-centrin, while faintly detectable at some
interphase centrosomes (Fig. S4), was most abundant in mitotic
cytoplasm and at mitotic spindle poles (Fig. 1A, fourth column). A
robust increase in Aurora A at mitotic spindle poles compared to
interphase cells (Figures S4+S6) in prophase was accompanied by
markedly intense p-S170 centrin staining (Fig. 1A; prophase). This
dramatic and specific appearance of p-S170 centrin co-localizing
with Aurora A in early prophase cells persisted throughout
metaphase. Subsequently p-S170 centrin diminished during
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centrin returned to basal interphase levels (Fig. 1A; metaphase
through telophase). Reciprocal immunoprecipitations from double
thymidine/nocodazole-synchronized cells demonstrate that Auro-
ra A and centrin both not only localize to the centrosome but can
be physically complexed during mitosis (Fig. 1B). Together these
experiments show that phosphorylated centrin levels are highest
when Aurora A is active [22,23], and that Aurora A and p-S170
centrin both localize and interact during mitosis.
To determine if this interaction has functional consequences, we
performed a kinase assay using recombinant, bacterially-expressed
Aurora A as well as Aurora A immunoprecipitated from
Figure 1. Aurora A localizes with and phosphorylates centrin in vitro and in cells. (A) Immunofluorescence confocal microscopy of HeLa
cells demonstrates that Aurora A (green) and phospho-S170 centrin (red) both localize at mitotic spindle poles from prophase through metaphase.
Phospho-centrin is greatly reduced in anaphase and telophase and Aurora A is greatly reduced by telophase. DNA was counterstained with DAPI
(blue). Scale bar=10 microns. (B) Western blots of whole cell lysates (WCL) from cycling and nocodazole-arrested mitotic cells show that centrin and
Aurora A are present in asynchronous and synchronous cultures, with greater amounts of Aurora A in mitotic cells. Reciprocal immunoprecipitations
(IPs) of mitotic cell lysates demonstrate an interaction between Aurora A and centrin during mitosis. (C) In in vitro kinase assays with recombinant
centrin incubated with recombinant Aurora A, centrin was phosphorylated only in the presence of ATP. Under conditions containing ATP, a shift in
centrin is detected when Western blotted with a total centrin antibody (lower panel) and phospho-centrin is detected by the phospho-S170 centrin
antibody (upper panel). Phospho-centrin is not detected under conditions lacking Aurora A and/or ATP. (D) In vitro kinase assays using endogenous
Aurora A immunoprecipitated from nocodazole-arrested HeLa cells generated phospho-centrin only in the presence of ATP as demonstrated by
Western blotting with the phospho-S170 centrin antibody. (E) Kinase-active Aurora A is required for phosphorylation of centrin at mitotic spindle
poles. Cells that lack endogenous Aurora A but express shRNA-resistant GFP-WT Aurora A clearly exhibit phospho-S170 centrin (red) staining; while
those that lack endogenous Aurora A and express GFP-kinase dead Aurora A exhibit a nearly complete loss of phospho-S170 centrin (red) staining at
the mitotic spindle poles. White arrows denote the focal staining of gamma-tubulin (turquoise) at poles in the cell expressing WT Aurora A or kinase
dead Aurora A (green).
doi:10.1371/journal.pone.0021291.g001
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immunoprecipitated Aurora A phosphorylate centrin in vitro,
resulting in a gel shift as detected using a monoclonal antibody
against total centrin and using an antibody specific for centrin
phosphorylated at S170 (Fig. 1C, D). As a control, we performed
an in vitro kinase assay solely with centrin and ATP to demonstrate
that centrin cannot phosphorylate itself. Mass spectrometry of the
excised gel-shifted band from the lane containing: Aurora A,
centrin, and ATP confirmed that centrin was phosphorylated at
serine 170, as well as at serine 122, in the presence of Aurora A
and ATP (data not shown). Both of these sites, (
120KISF
123 and
168KTSL
171) match the Aurora A substrate consensus sequence
(R/K-x-T/S-I/L/V/F) [24,25]; in this study we focused on the
serine 170 phosphorylation site, which occurs near the carboxy-
terminus of centrin.
To further confirm that Aurora A mediates phosphorylation of
centrin in cells, we knocked down Aurora A using a plasmid based
shRNA directed against the 39 UTR of the Aurora A mRNA. A
Western blot of cell lysates from transfections of the vector control
and Aurora A shRNA vector is shown in Figure S2. The mitotic
index was reduced to 20% of vector only controls following knock
down of Aurora A. In experiments where endogenous Aurora A
was knocked down, expression of shRNA-resistant recombinant
wildtype Aurora A, but not kinase dead (K162R) Aurora A,
rescued the bipolar spindle phenotype and showed intense focal
staining with antibodies against gamma-tubulin and p-S170
centrin at the poles of mitotic cells (Fig. 1E). Although bipolar
spindles still formed in the presence of kinase dead Aurora A, we
noted that the spindle poles lacked focal p-S170 centrin when
compared to cells expressing shRNA-resistant-GFP-WT Aurora
A. These experiments demonstrate that Aurora A is a physiolog-
ically relevant kinase that localizes at the centrosome with centrin
and phosphorylates centrin at mitotic spindle poles. In addition,
cells over-expressing Aurora A have higher level of centrin and
phosphorylated centrin than do cells expressing empty vector (Fig.
S5).
Because the level of phospho-centrinremainshighfrom prophase
through metaphase but abruptly decreases at the onset of anaphase
(Fig. 1A, anaphase), we sought to determine if the phosphorylation
ofcentrin mayplaya role intheregulationofcentrin stabilityduring
the cell cycle. To accomplish this, we established stable HeLa Tet-
On cell lines expressing different recombinant HA-tagged centrin
mutants that alter the serine residue 170 phosphorylation site: 1)
wildtype centrin (
167KKTSLY
172, WT); 2) a truncation mutant in
which the C-terminal six amino acids of centrin were deleted
(
167kktsly
172, trunc); 3) a non-phosphorylatable mutant centrin
(
167KKTALY
172, S170A); and 4) a mutant that mimics constitutive
centrin phosphorylation (
167KKTDLY
172, S170D). Unless other-
wise stated, all experiments were performed in the presence of
endogenous centrin. In order to assess the half-life of these HA-
taggedcentrinrecombinantproducts,weperformed a‘‘pulse/wash-
out’’ experiment by inducing their expression with doxycycline for
12 hours, followed by washing with and incubation in doxycycline-
free medium over a time-course. The half-life of the wildtype HA-
centrin (WT),
167KKTSLY
172, and the non-phosphorylatable
centrin,
167KKTALY
172 (S170A), were approximately 11 and
12 hours respectively, indicating a near complete turnover once per
approximately 24-hour cell cycle period (Fig. 2A, B). The lack of
significant differences betweenthe WT and S170A mutanthalf-lives
is likely because only a small pool of centrin (the centrosomal pool)is
phosphorylated in a cell cycle dependent fashion. Conversely, the
truncationmutant(trunc),
167kktsly
172,wasstrikinglyunstablewitha
protein half-life of approximately 4.1 hours. Notably, a dramatic
increase in half-life of the
167KKTDLY
172 (S170D) mutant protein
(approximately 21 hours) was observed (Fig. 2A, B). Due to the
striking differences in the half-lives of the wildtype and mutant
centrins, we performed cell counts to determine if these mutants
affect cell proliferation when endogenous centrin is knocked down
and the HA-tagged centrins were expressed. As demonstrated by
graph in Figure 2C, the S170D centrin expressing cells rescued the
centrin depletion phenotype [17] at least as well as, if not better
than, the wildtype centrin expressing cells did. On the other hand,
the two centrin mutants that were non-phosphorylatable either due
topointmutation(S170A)ordeletion(kktsly)werenotable torescue
the centrin depletion phenotype and proliferated at a much slower
rate similar to the rate seen when Aurora A is knocked down
(Fig. 2C).
Due to the abrupt loss of phospho-centrin after anaphase
( F i g .1 A ) ,w ep e r f o r m e dd o u b l et h ymidine/nocodazole-synchro-
nization, shake-off, and release experiments to determine if the
total level of centrin fluctuates during cell cycle. Figure 3A
illustrates that both Aurora A and centrin abundance peak in
G2/M (nocodazole) compared to cycling cells and remain high
for 60–90 minutes after release from nocodazole treatment. At
120 minutes post-release, Aurora A levels begin to drop; this
occurs prior to significant decreases in centrin although there is
a slight transient decrease in centrin at 60 minutes post-release.
Nonetheless, by 150 minutes both Aurora A and centrin have
reached levels comparable to or lower than cycling cells. Cyclin
B degradation, which begins 60 minutes after nocodazole
release, indicates the physiological onset of metaphase
(Fig. 3A). FACS analysis confirms that cell cycles were
synchronized and shows cells entering G1 as early as 60 minutes
after nocodazole release (Fig. S1). This experiment demonstrates
temporally coincident expression, accumulation, and post-
metaphase decrease of both Aurora A and centrin during the
cell cycle.
We reasoned that the decrease in centrin levels could be due
to proteasomal degradation because, after peaking in early
mitosis, centrin appears to decrease as mitosis progresses to
anaphase, when Aurora A and cyclin B also decrease due to
proteasome-mediated degradation. The timing of mitotic
decrease in centrin protein suggested that centrin could be an
anaphase promoting complex/cyclosome (APC/C) substrate.
Consistent with this hypothesis, we identified a destruction box
(D-box) (
151RDgdGEVSe
159) within centrin’s protein sequence
that closely matches the D-box of the canonical mitotic APC/C
substrate cyclin B (http://bioinfo2.weizmann.ac.il/,danag/
dbox/form.html). As shown in Figure 3B, centrin immunopre-
cipitates with cdc20, an activator and substrate binding subunit
of the APC/C. Cdc20 immunoprecipitations demonstrate that it
interacts with other units of the APC/C, cdc16 and cdc27
(Fig. 3B). Cdc20 immunoprecipitations from asynchronous
HeLa cell lysates illustrate that centrin, but not p-S170 centrin,
forms a complex with cdc20 (Fig. 3C). These data support the
notion that phosphorylated centrin is more stable than unpho-
sphorylated centrin perhaps because the phosphorylated form
does not interact with the APC/C protein degradation
machinery.
These results led us to further investigate centrin degradation by
treating HeLa Tet-On centrin cell lines overnight with a serine
protease inhibitor (leupeptin, L), a lysosomal inhibitor (ammonium
chloride, N), and two proteasome inhibitors (ALLnL, A and
MG132, M), to determine the mechanism of centrin degradation.
The lysosome and serine protease inhibitors did not alter the level
of centrin in any of the mutants; although the centrin truncation
mutant appears to be intrinsically unstable and is likely degraded
quickly via an alternative constitutive mechanism (see Discussion).
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greatly increased in cells treated with either proteasome inhibitor,
indicating that these centrins are degraded via the proteasome
(Fig. 3D). Western blots of lysates from HeLa Tet-On cells
expressing the S170A centrin mutant treated with the proteasome
inhibitor ALLnL demonstrated a laddering of approximately
7 kDa increments when probed with an anti-centrin antibody,
consistent with ubiquitination of centrin (Fig. 3E). This laddering,
the canonical D-box, and the physical interaction of centrin in a
complex containing cdc20, cdc27, and cdc16 suggest that centrin
is degraded by ubiquitin-mediated mitosis-specific APC/C
activities.
To investigate the consequences of centrin phosphorylation in
cells, endogenous centrin was knocked down using a plasmid
based shRNA directed against the 39 UTR of centrin 2 in HeLa
Tet-On cells left untreated (Fig. 4B) or treated with doxycycline to
induce expression of the S170D centrin mutant (Fig. 4A).
Expression of the S170D mutant resulted in a dramatic increase
in HA-tagged centrin staining as compared to untreated cells, and
this was accentuated in cells when endogenous centrin was
knocked down (Fig. 4A). Detailed electron microscopic studies of
the S170D centrin expressing mutant, described elsewhere (Salis-
bury et al, in preparation), demonstrate that these cells exhibit
aberrant centriole-like structures, which may explain the excess
centrin staining we observe in Figure 4A. Because this accumu-
lation of centrin resembles centrosome aberrations seen in breast
cancer [26] and human breast tumors frequently over-express
Aurora A, we extended our studies of phospho-centrin to human
breast tumors. Examination of frozen sections of normal breast
epithelium adjacent to tumor tissue stained with antibodies
directed against Aurora A, gamma-tubulin, and p-S170 centrin
show low levels of Aurora A and p-S170 centrin staining at the
centrosome (Fig. 4G) consistent with the low proliferative rate of
normal breast tissue. In contrast, ductal carcinoma in situ (Fig. 4H)
and invasive breast tumor tissues (Fig. 4I) displayed both increased
size [27] and number of centrosomes (amplified centrosomes or
more than two centrosomes per cell) [28], as marked by gamma-
tubulin, with striking co-localization of Aurora A and p-S170
centrin. These observations are consistent with what we observed
in normal and cancerous breast tissues in our previous study [27].
This is consistent with our observation that expression of the
S170D phospho-centrin mutant results in increased centrin-foci in
cultured human cells and that Aurora A and phospho-centrin co-
localize at amplified centrosomes in human breast tumors.
To determine if the phosphorylation of centrin at serine 170 is
necessary for Aurora A-mediated centrosome amplification, we
utilized two of the doxycycline HA-tagged centrin mutant
expressing HeLa Tet-On cell lines: HA-S170A centrin and HA-
WT centrin with the expectation that cells expressing only non-
phosphorylatable centrin would not develop amplified centro-
Figure 2. Engineered mutations at S170 affect centrin protein
stability and cell proliferation rates in HeLa. (A) Western blotting
of whole cell lysates of cells expressing inducible HA-tagged mutant
centrin constructs (bHA) at time points following doxycycline washout
reveals that the truncated centrin mutant has the shortest half-life, the
S170D mutant that mimics phosphorylated centrin has the longest half-
life, while endogenous wildtype centrin (bE) remains fairly constant. (B)
The half-lives of the centrin mutants were determined by plotting the
changes in optical density plots of the Western blots shown in (A) for 5
independent experiments. The S170A and wildtype half-lives are
virtually the same at 12.2 and 10.9 hr respectively (p=0.942). The
S170D half-life, at 20.7 hr, is significantly longer than either S170A or
wildtype (p,0.027 and 0.013, respectively). In 3 of 5 experiments, the
half-life of the truncation mutant could not be determined because the
time points measured were not early enough. Results of the 2
experiments in which it could be analyzed indicate the half-life of the
truncation mutant is approximately 4.1 hr. (C) Proliferation rates of cells,
normalized to HA-tagged wildtype centrin, in which centrin has been
knocked down by shRNA and then induced to express only engineered
centrin mutants reveal that the truncation mutation greatly reduces the
growth rate less than 30% of cells expressing wildtype centrin by 48 hr.
Likewise, the S170A mutant (KKTALY) reduces growth rate to
approximately 40% at 72 hr. The S170D mutant (KKTDLY), which
mimics centrin phosphorylated at serine 170, rescues the centrin
depletion phenotype to a slightly greater extent than does wildtype
centrin. The error bars represent standard deviation of three
independent experiments. * indicates p values#0.03 when compared
to wildtype or the S170D centrin construct.
doi:10.1371/journal.pone.0021291.g002
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GFP-WT Aurora A was over-expressed in the HA-WT centrin
and HA-S170A centrin cell lines for 24 hours, then the cells were
transfected with either control shRNA or 39 UTR centrin specific
shRNA. Four hours after transfection of the shRNA constructs,
the cells were induced with doxycycline and allowed to grow for an
additional 24 or 48 hours. Cells were then stained for total centrin
and gamma-tubulin and analyzed by immunofluorescence confo-
cal microscopy. GFP positive cells were analyzed to ensure we
were selecting GFP-WT Aurora A expressing cells. One hundred
percent of GFP-WT Aurora A expressing cells exhibited
centrosome amplification (Fig. 4C, n=27). Cells expressing HA-
Figure 3. Centrin interacts with APC/C during mitosis. (A) Levels of Aurora A, centrin, and cyclin B were compared in Western blots of lysates of
HeLa cells harvested at the indicated time points after synchronization by double thymidine/nocodazole block and release. Cyclin B degradation is
used to indicate the onset of anaphase, while the beta-actin blot serves as a loading control. Aurora A and centrin levels drop to basal levels by
150 minutes post-release, while cyclin B is at basal levels by 120 minutes post-release. (B) Equal volumes of immunoprecipitations of lysates from
cycling (C) or nocodazole arrested (N) HeLa cells performed with Cdc20 and centrin and Western blotted with the indicated antibodies demonstrate
that centrin is pulled down with cdc20 only in nocodazole arrested cells along with Cdc16 and Cdc27. Cdc20 is pulled down with centrin in
nocodazole arrested cells and to a slightly lesser extent in cycling cells. The antibody heavy chain and cdc20 were indicated with (b) and (b),
respectively. (C) In lysates from asynchronously growing HeLa cells only non-phosphorylated centrin immunoprecipitates with cdc20. Cdc20 does not
pull down phosphorylated centrin even though p-S170 centrin is abundant, as seen in the lysate-only lane. (D) HeLa Tet-On cells expressing various
centrin mutants treated overnight with DMSO (D), ALLnL (A), leupeptin (L), MG132 (M), and ammonium chloride (N) and Western blotted with
antibodies directed against total centrin reveal that DMSO, leupeptin, and ammonium chloride do not prevent centrin degradation, whereas ALLnL
and MG132, the two proteasome inhibitors, do prevent degradation of wildtype and mutant forms of centrin. Lamin B loading controls are shown for
each mutant cell line. (E) Lysates from HeLa Tet-On cells expressing S170A centrin treated with DMSO (D) or ALLnL (A) for 16 hours were Western
blotted for centrin and beta-actin show significant degradation products in the presence of ALLnL but not DMSO. Additionally, when the boxed area
of the centrin blot is over-exposed, 7 kDa laddering indicative of ubiquitination is evident (D). Endogenous and HA-centrin are indicated with (c) and
(c), respectively.
doi:10.1371/journal.pone.0021291.g003
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Tet-On S170D-centrin cells treated continuously with doxycycline. Cells were stained with an antibody against HA (green) and a polyclonal antibody
against centrin (red). Scale bar=10 microns. (B) Cells that were not induced with doxycycline have normal centrosomes. Cells were stained as in panel
(A). Scale bar=10 microns. (C–F) HeLa Tet-On HA-WT-centrin or HA-S170A-centrin cells transfected with GFP-WT Aurora A and allowed to recover for
24 hours. Cells were then transfected with control shRNA or centrin shRNA and treated with doxycycline to induce HA-centrin expression. Aurora A
expression was noted by GFP positivity and cells were stained with centrin (red) and gamma-tubulin (turquoise). A vector control Western blot is
shown in Figure S3. Cells over-expressing HA-wildtype centrin in the presence of endogenous centrin have large, numerous centrosomes (C) in
virtually all cells. Cells over-expressing HA-wildtype centrin in the absence of endogenous centrin have large, numerous centrosomes (D) in most
cells. Conversely cells over-expressing HA-S170A centrin in the presence of endogenous centrin occasionally have slightly enlarged centrosomes (E)
and cells over-expressing HA-S170A centrin in the absence of endogenous centrin rarely have slightly enlarged centrosomes (F). GFP positive cells
were analyzed for centrosome amplification based on increased size and/or number of centrosomes. The number and percentage of cells with
centrosome amplification is presented below each panel. Scale bar=2.5 microns. (G–I) Frozen breast tissue including normal adjacent breast (G),
ductal carcinoma in situ (H) and invasive breast cancers (I) were stained with antibodies directed against Aurora A (green), p-S170 centrin (turquoise),
and gamma-tubulin (red). Cells were stained with DAPI to mark the DNA. Scale bar=10 microns.
doi:10.1371/journal.pone.0021291.g004
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centrosome amplification in the great majority of cells (84% of
cells; Fig. 4D, n=32). Figure S3 shows the expression of HA-
centrin while endogenous centrin is knocked down. Approximately
half of the cells expressing S170A centrin in the presence of
endogenous wildtype centrin exhibited centrosome amplification
(56%; Fig. 4E, n=32), while cells expressing only S170A centrin
demonstrated a dramatic decreased in centrosome amplification to
7% (Fig 4F, n=30). Together with the S170D centrin experiments
(Fig. 4A, B), these experiments clearly demonstrate that Aurora A-
dependent phosphorylation of centrin is sufficient to cause
centrosome amplification and the extent of amplification directly
correlates with the expression levels of S170-phosphorylatable
centrin.
Discussion
We previously demonstrated phosphorylation of centrin at
serine 170 by PKA [17]. Here we show that Aurora A is another
such kinase, which we demonstrate is the relevant mitotic kinase
that mediates centrin stability at the time of cell division. This does
not preclude a role for PKA in centrin phosphorylation under
other physiological circumstances. The precise manner in which
excess phosphorylated centrin causes centrosome amplification is
not known. One possibility is that the increased stability of centrin
directly affects centriole formation through mass action equilibri-
um binding due to centrin accumulation. Alternatively, p-S170
centrin may adopt a conformation that affects its interaction with
other centriole proteins leading to nascent centriole-like structure
assembly.
It is also worth noting that centrin’s stability is severely affected
when the six carboxy-terminal amino acids are deleted (centrin
truncation mutant kktsly). These observations coupled with the
analysis of the phosphorylation status within this C-terminal tail
suggest that these amino acids are essential for proper centrin
stability. It is likely that centrin is misfolded without its C-terminal
6 amino acids. Hydrophobic residues are often exposed when
proteins are incorrectly folded and this can lead to aggregation of
the misfolded proteins. Cells have two main mechanisms for
dealing with misfolded proteins: repair and proteolysis [29,30,31].
These mechanisms involve both chaperones and the proteasome,
but the details of cytosolic protein ‘‘quality control’’, as compared
to endoplasmic reticulum (ER) mechanisms, are currently poorly
understood [29,30,31]. If refolding of truncated centrin by
molecular chaperones, like the heat shock proteins, is not
successful, then the truncated centrin would likely be degraded
as part of the cytosolic quality control mechanism. Interestingly,
the chaperones, Hsp90 and Hsp70, localize to the centrosome and
interact with centrin in Xenopus [32]. Several published accounts
describe the proteasome at the centrosome lending credence to the
idea that truncated centrin could be degraded at the centrosome
[33,34]. While it is possible that a truncation mutation of centrin
could occur naturally, we chose to focus on the phosphorylation
status because we observed centrin phosphorylation in unper-
turbed cells.
Because both Aurora A and centrin are located at the
centrosome and manipulation of either protein can alter the
centrosome cycle, we investigated the association between these
two proteins. We found that Aurora A and pS170-centrin interact
with one another and are both located at the centrosome
throughout the cell cycle. Importantly, we show that Aurora A is
necessary for the focal localization of phospho-S170-centrin at
mitotic spindle poles. Our studies show that Aurora A phosphor-
ylates centrin at serine 170 in vitro and that the serine 170
phosphorylation affects the stability of centrin by regulating its
interaction with APC/C. Furthermore, we found that over-
expression of a centrin mutant that mimics phosphorylation results
in accumulation of centriole-like structures in cultured cells and
that excess Aurora A and phospho-centrin accumulate at
amplified centrosomes of human breast tumors. Expression of
the phospho-centrin mimicking mutant can rescue the centrin
depletion phenotype, whereas expression of the non-phosphor-
ylatable mutant and the truncation mutant lacking the phosphor-
ylation site cannot rescue the phenotype. Finally we demonstrated
that phosphorylation of centrin serine 170 is an absolute
requirement for Aurora A-mediated centriole amplification.
Our studies demonstrate that Aurora A mediates phosphory-
lation of centrin at serine 170 in a cell cycle dependent fashion.
Strikingly, the pattern of accumulation and then decrease of
phospho-centrin during the course of mitosis is consistent with that
observed for many other centrosome-associated proteins. Pro-
nounced accumulation of phosphorylated centrosomal proteins at
the onset of prophase has been described previously [35]. Loss of
phospho-proteins can be due to the dephosphorylation and/or
degradation of phosphorylated proteins. We propose that Aurora
A-mediated phosphorylation of centrin at late G2/M transiently
stabilizes the protein until its dephosphorylation at the metaphase-
anaphase transition, allowing for its recognition by the APC/C-
machinery, ubiquitination, and consequent proteasomal degrada-
tion.
Aurora A can stabilize various proteins via kinase activity-
independent and -dependent mechanisms. Both E2F1 and N-myc
proteins are stabilized by Aurora A independent of its kinase
activity [36,37]. Aurora A’s ability to phosphorylate GSK3beta
indirectly protects beta-catenin from GSK3beta-mediated phos-
phorylation and subsequent proteasomal degradation [38].
Interestingly, Aurora A expression stabilizes ASAP protein levels
by preventing its proteasomal degradation, and although, Aurora
A directly phosphorylates ASAP, it is unclear if this phosphory-
lation is responsible for ASAP protein stabilization [39].
Additionally, Aurora A’s kinase activity is required for stabilization
of cyclin B and its APC/C-mediated proteasomal degradation. But
again it is unclear if Aurora A must directly phosphorylate cyclin B
for this to occur [40]. Phosphorylation is known to impact the
stability of a number of APC/C substrates including cdc6 and
Aurora A [41,42,43].
Here we show that non-phosphorylated, endogenous centrin
interacts with APC/C components cdc20, cdc16, and cdc27, that
specific proteasome inhibitors block the degradation of centrin,
and that centrin mutated to resemble constitutive phosphorylation
at serine 170 (KKTDLY, S170D) is more stable than either
wildtype or non-phosphorylatable centrin (KKTALY, S170A).
Furthermore, kinetic analysis of the degradation of specific centrin
mutants shows that wildtype or non-phosphorylatable centrins
have a half-life of approximately 11 hours, which is consistent with
its degradation once during cell cycle. Interestingly for Aurora A,
phosphorylation also plays a protective role against proteasomal
degradation [41]. Phosphorylation of Aurora A at serine 51 (S51)
protects it from APC/C
cdh1-mediated ubiquitination and subse-
quent proteasomal degradation [41]. Similar to centrin, a non-
phosphorylatable mutation in Aurora A (S51A) has a shorter
protein half-life than wildtype Aurora A [41]. Centrin therefore
joins Aurora A and a growing list of cell cycle proteins whose
abundance is regulated by phosphorylation and APC/C-mediated
destruction.
Proteasomal degradation plays a critical role in regulation of a
number of diverse cell cycle components. Among those associated
with centrosome behavior are the degradation of cyclin B during
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and centriole disengagement late in mitosis [45,46]. Duensing and
colleagues demonstrated that treatment of U2OS cells with Z-
L3VS, which inhibits the trypsin, chymotrypsin, and peptidylglu-
tamyl peptidase activities of the proteasome, led to centrosome
over-duplication characterized by a mother centriole surrounded
by a rosette of daughter centrioles [1]. These data illustrate that a
functional proteasome is essential for centrosome homeostasis. In
light of our observations demonstrating that centrin accumulates
in the presence of proteasome inhibitors, we speculate that lack of
centrin degradation could contribute to the proteasome inhibitor-
induced centrosome aberrations.
Interestingly while we were performing revisions on this
manuscript, Yang et al. demonstrated that Mps1 phosphorylates
centrin-2 at three sites (T45, T47, and T118 or centrin
TTT) in vitro
[47]. The authors demonstrate that over-expressing GFP-tagged
centrin-2 causes excess centrioles and that non-phosphorylatable
centrin mutants, centrin
AAT and centrin
TTA, greatly reduce the
over-production of centrioles [47]. Phospho-mimicking centrin
mutants, centrin
DDT, centrin
TTD, and centrin
DDD, showed
increased formation of excess centrioles, but all three phosphor-
ylation sites were required [47]. Previously the Fisk lab
demonstrated that non-degradable centrosomal Mps1 can cause
centriole over-production [48]; and in this manuscript, they
demonstrate that centrin-2 is required for this process [47].
Interestingly by further studying the over-production of centrioles,
Yang et al. demonstrated that over-expression phospho-mimicking
centrins mutants can not compensate for a reduction in Mps1 in
this process [47]. Because the triple centrin-2 phospho-mimic can’t
compensate for lack of Mps1, this argues that there are other
unidentified phosphorylation sites within centrin-2 or other Mps1
substrates that contribute to this process [47]. These along with
other recent findings [49] suggest that centrin-2 regulation
including its role in centrosome homeostasis could be far more
complicated than originally appreciated.
Materials and Methods
Ethics Statement
Frozen breast tissues were collected by the Mayo Clinic Breast
SPORE Program under the Mayo Clinic Internal Review Board
approval # 08-008233. This IRB-approved Protocol allows for
use of tissues collected during standard patient care procedures
without patient consent, therefore no consent was obtained.
‘‘Continuation of the above referenced study is approved by
expedited review procedures (45 CFR 46.110, item 5). The
Reviewer determined the research continues to pose no more than
minimal risk to subjects. The Reviewer determined that this
research continues to satisfy the requirements of 45 CFR 46.111.’’
Reagents
All chemicals were purchased from Sigma (St. Louis, MO)
unless otherwise stated.
Antibodies
Antibodies were purchased from the following sources:
monoclonal Aurora A clone 35C1 (AbD Serotec; Raleigh, NC),
polyclonal Aurora A, goat polyclonal cdc16, monoclonal and
polyclonal cdc20, and monoclonal cdc27 (Santa Cruz Biotechnol-
ogy Inc.; Santa Cruz, CA), cyclin B (Cell Signaling Technology;
Danvers, MA), HA-tag (Covance; Princeton, NJ), and b-actin
(Sigma). Monoclonal centrin (20H5), polyclonal centrin (MC1),
and p-S170 phospho-centrin antibodies were created in the
Salisbury laboratory.
Cell culture
HeLa cells were maintained in DMEM with 10% FBS, 100 IU/
ml penicillin, and 100 mg/ml streptomycin. HeLa Tet-On cells
were cultured in DMEM with 10% Tet System Approved FBS
(Clontech; Mountain View, CA), 100 IU/ml penicillin, 100 mg/ml
streptomycin, 400 mg/ml hygromycin, and 100 mg/ml geneticin.
To induce expression of HeLa Tet-On cells containing centrin
constructs, doxycycline was added to the medium at a final
concentration of 1 mg/ml.
Cell synchronization techniques
For the double thymidine/nocodazole synchronization, HeLa
cells were grown to approximately 80% confluency, treated with
2 mM thymidine for 12–16 hours, and released into medium
containing 24 mM deoxycytidine for 9 hours. The second block
was done as described above except the deoxycytidine release was
only 8 hours. Cells were treated with 0.1 mg/ml nocodazole for six
hours, harvested by mitotic shake-off, washed, and allowed to
release in nocodazole-free medium. For the nocodazole synchro-
nization, cells were treated with 0.5 mg/ml nocodazole for 12–
16 hours and harvested as previously described.
Western blotting
Cells were lysed in 1% SDS, Tris pH 7.4 lysis buffer
supplemented with protease and phosphatase inhibitors and
sonicated three times for five seconds/burst. Protein concentration
was determined using the BioRad DC Assay. For whole cell lysate
Western blotting, 20 mg of protein was separated on 10% or 15%
SDS-PAGE gels. After separation, proteins were transferred to
PVDF membrane using a semi-dry transfer apparatus (The
W.E.P. Company, Seattle, WA), fixed with 0.2% glutaraldehyde
for 45 minutes at room temperature, blocked with 5% non-fat dry
milk for at least 1 hour at room temperature, and incubated with
the indicated antibodies overnight at 4uC. Membranes were
incubated in secondary antibodies (GE Healthcare; United
Kingdom) diluted to 1:2500 for one hour at room temperature
and visualized with ECL (ECL anti-rabbit or anti-mouse IgG-
HRP; GE Healthcare; anti-goat IgG-HRP; Santa Cruz) according
to manufacturer’s instruction.
Flow Cytometry
Cells were harvested by trypsinization, fixed in 95% ethanol,
incubated on ice for at least one hour, washed three times, and
stained with propidium iodide (100 mg/ml in 0.1% sodium citrate).
DNA content of cells was determined by measuring the propidium
iodide staining on channel FL2 using a Becton Dickinson
FACScan (San Jose, CA).
Immunoprecipitations (IP)
HeLa cells were grown to 85–90% confluence, lysed in 200 mlo f
mild lysis buffer (1% NP-40, 10 mM EDTA, 10 mM Tris-HCl,
pH 7.4 with protease inhibitors and phosphatase inhibitors),
scraped and collected into a microfuge tube. Cell lysates were
sonicated three times at 5 seconds/bursts. IP buffer A (190 mM
NaCl, 50 mM Tris-HCl, 6 mM EDTA, 2.5% Triton X-100,
pH 7.4) was added to each tube to bring the cell lysate volume up
to 1 ml. Each IP was spun down at 14,000 rpm for 5 minutes, and
the supernatant was removed and placed into a new microfuge
tube. Six ml of antibody was added to each IP and rocked
overnight at 4uC. The next day, 50 ml of Pierce A/G beads
(Pierce, Rockford, IL) was added to each IP and allowed to rock at
4uC for 1 hour. IPs were spun down at14,000 rpm for 1 minute to
pellet the beads and washed 3 times with IP buffer A and 3 times
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0.1% Triton X-100, pH 7.4). After the final wash, the supernatant
was removed and 50 mlo f4 6 SDS sample buffer were added.
Samples were boiled for 5 minutes at 100uC, spun down, and
separated by SDS-polyacrylamide gels for Western blotting.
In vitro kinase assay and mass spectrometry
For each reaction, 200 units of recombinant Aurora A (Cell
Biosciences; Palo Alto, CA) were incubated with 1 mg recombinant
centrin-2 for 30 minutes at 30uC in the presence or absence of
10 mM ATP in kinase buffer (50 mM Tris, 10 mM MgCl2,
0.16 mg/ml DTT, pH 7.4). After the initial 30 minutes, another
10 mM ATP, or equivalent volume of kinase buffer minus ATP,
was added and the mixture was allowed to incubate for an
additional 30 minutes at 30uC. The reaction was stopped by
adding SDS buffer to the samples and boiling the samples. The
kinase reactions plus and minus ATP were separated by SDS-
PAGE, Coomassie stained, and sent for mass spectrometry
analysis to determine phosphorylated residues in centrin.
Immunofluorescence and microscopy
Cells were grown on coverslips, washed once with MTSB (3 mM
EGTA, 50 mM PIPES, 1 mM magnesium sulfate, 25 mM
potassium chloride), and fixed in 220uC methanol for 10 minutes.
Coverslips were dried at room temperature, rehydrated in 0.05%
triton X-100/PBS for 3 minutes, and blocked in goat blocking
buffer (5% goat serum, 1% glycerol, 0.1% BSA, 0.1% fish skin
gelatin, 0.04% sodium azide, pH 7.2) for at least 30 minutes.
Coverslips were incubated in primary antibody for 1 hour at room
temperature, washed three times with PBS, incubated in secondary
antibody for 1 hour at room temperature, and washed again as
above. Coverslips were post-fixed in 4% EM grade paraformalde-
hyde (Electron Microscopy Sciences, Hatfield, PA) in PBS for five
minutes, washed twice, dried, and mounted onto slides with
ProLong Gold reagent with DAPI (Invitrogen, Carlsbad, CA).
Tissues were treated as described above but were freshly
cryosectioned from frozen breast tissue the day of the staining and
the MTSB wash step was omitted. Images were collectedas Z-stacks
on a LSM 510 Confocal Laser Scanning Microscope (Zeiss,
Germany) for all images except those in Figure 4A+B, which were
collected on a Zeiss Axioskop. To improve their quality, we
performed minimal image adjustmentson them using PhotoShop as
follows. Using ‘‘Levels’’, both images had their RGB input settings
changed to 10, 0.79, and 255. The inset images had blue removed.
The inset images then had the green levels adjusted to minimize
the green ‘‘haze’’ from the GFP transfection marker so that the
green AlexaFluor 488 signal was clearer. No other post-capture
image processing was performed.
Stable HeLa Tet-On centrin mutant cell lines
The HeLa Tet-On system was purchased from Clontech.
Mutations in the centrin-2 sequence, cloned into the pTRE2hygro-
HA vector, were created using site-directed mutagenesis. The
constructs were transfected into HeLa Tet-On cells containing the
pTRE-Tight vector using FuGene 6 (Roche) according to manufac-
turer’s instructions. Stably transfected cells were selected by exposing
cells to hygromycin and screened using doxycycline induction.
Pulse/wash-out experiments and proteasome inhibition
For pulse/wash-out experiments, HeLa Tet-On cells were
treated with doxycycline for 12 hours, washed with DMEM
medium, then incubated in normal Tet-On growth medium lacking
doxycycline. Samples were harvested at indicated times and lysed in
SDS lysis buffer as described above. For proteasome inhibition
studies, cells were incubated with DMSO as a vehicle control,
100 mM ALLnL or MG132, 20 mM ammonium chloride, or
10 mM leupeptin for at least six hours. Cells were then harvested at
indicated times and lysed in SDS lysis buffer containing N-
ethylmaleimide (NEM) at a final concentration of 1 mg/ml.
Expression vector and shRNA construction and knock
down of Aurora A and centrin
Aurora A cDNA (NCBI accession # NM_003600.2) was
purchased from Origene. It was amplified by standard PCR and
cloned into pEGFP-C3 vector (Clontech). shRNA oligos directed
against the 39 UTR of Aurora A (TAGGGATTTGCTTGG-
GATA) were annealed and cloned into an RNA polymerase III
dependent H1 RNA promoter driven vector. The same process
was repeated for the shRNA directed against the 39UTR of
centrin-2 (AGCTTTGAGCACCTGCCATTT). HeLa and HeLa
Tet-On cells were transfected with the Aurora A expression
vectors and/or Aurora A or centrin-2 shRNA using Lipofectamine
2000 (Invitrogen) according to manufacturer’s instructions.
Doxycycline was added to the cells 4 hours post-transfection and
cells were harvested at the indicated times and counted for cell
proliferation assays or lysed for Western blot analysis.
Statistical analysis
Centrin mutant half-life was determined by plotting the optical
density of Western blot analyses normalized against beta-actin
optical density for each mutant at each time point in 5
independent experiments. A linear trendline was plotted for each
curve, and the half-life was determined from the slope of the
trendline. The resultant half-life values for each mutant were
averaged and the standard deviation and standard error were
calculated. The probability that variances between the mutants
were not significantly different was determined using an F-test. For
the cell proliferation assay probability, a paired Student’s T Test
was performed on the data normalized against the wildtype results.
Supporting Information
Figure S1 DNA content of synchronized HeLa cells. HeLa cells
harvested at the indicated time points after synchronization by double
thymidine/nocodazole block and release. Cells were fixed with
ethanol and stained with propidium iodide to measure DNA content.
(DOC)
Figure S2 Aurora A knock down in HeLa cells. HeLa cells were
transfected with Aurora A shRNA and whole cell lysates were
harvested 24 hours after transfection. Whole cell lysates were
separated by SDS-PAGE and blotted with the indicated antibodies.
(DOC)
Figure S3 Centrin knock down in HeLa Tet-On HA-Centrin
expressing cells. HeLa cells were transfected with centrin shRNA and
whole cell lysates were harvested 48 hours after transfection. Whole
cell lysates were separated by SDS-PAGE and blotted with the
indicated antibodies. Note that it was possible to induce the expression
of HA-centrin (HA) while knocking down endogenous centrin (E).
(DOC)
Figure S4 Asynchronously cycling HeLa cells were fixed,
permeabilized, and processed for immunofluorescence as de-
scribed in the Material and Methods section. This image shows an
interphase HeLa cell exhibiting faint p-S170 centrin (red, denoted
with white arrowhead) co-localizing with Aurora A (green) staining
at the centrosome.
(DOC)
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pEGFP-C3 or pEGFP-C3-Aurora A constructs and cells were
harvested 48 hrs after transfection for immunoprecipitations using
anti-centrin and anti-phospho-centrin antibodies. Immunoprecip-
itations were separated by SDS-PAGE and blotted with anti-
centrin antibody. Note that there is more centrin and phospho-
centrin in the pEGFP-C3-Aurora A expressing cells.
(DOC)
Figure S6 HeLa cells were processed for immunofluorescence as
described in the Material and Methods section. Aurora A was
detected with an anti-Aurora A antibody (green) and DNA was
counterstained with DAPI (blue). An interphase cell is shown on
the left side and an early prophase cell on the right side of the
image. Note that Aurora A is much more abundant in the early
prophase cell. Scale bar=10 microns.
(DOC)
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